EUVIMEDEUVIMED entdecken
Multizentrische Studie

Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis

Kathrine Kelly, Lauren M Blanck, Kelvin Lim, Alexa Norman, Charlaine V Roberto, M Mura Assifi, G Paul Wright, Mathew Chung iD

The American Surgeon™ · 2023

DOI: 10.1177/00031348231156778 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The American Surgeon™, 2023. Verfasst von Kathrine Kelly und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Residency, Spectrum Health, Grand Rapids, MI, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Pulmonary Embolism. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients undergoing oncologic resection are at risk of developing venous thromboembolism (VTE), and this can lead to increased morbidity and hospital costs. Low-molecular weight heparin (LMWH) is recommended as extended thromboprophylaxis (ETP) in high-risk patients and has been shown to reduce rates of VTE.

Methods

This is a retrospective review of consecutive patients undergoing resection for oncologic indications at a single institution from May 2016 to May 2019. This study evaluated the use of apixaban as ETP at discharge. The primary outcomes were deep vein thrombosis (DVT), pulmonary embolism (PE), or mesenteric/portal venous thromboembolism at 30, 60, and 90 days postoperatively.

Results

A total of 600 patients were included; 449 patients received no ETP, and 151 patients received apixaban. PE occurred in 1.1, 1.6, and 2.3% of patients without ETP and 0, 0, and .7% of patients in the apixaban group (at 30, 60, and 90 days; P = .338, P = .201, and P = .306, respectively). DVT occurred in 1.8, 2.1, and 2.8% of patients without ETP and 0, 0, and 1.4% in the apixaban group ( P = .211, P = .121, and P = .535, respectively). The total cost, including ETP and readmission for VTE, per patient was US $5.51 more in the apixaban group.

Conclusion

Apixaban therapy for ETP did not produce a statistically significant reduction in VTE events in our patients. Future studies should include more patients in a prospective multicenter trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismPulmonary EmbolismHumansHeparin, Low-Molecular-WeightAnticoagulantsProspective StudiesCosts and Cost AnalysisPyrazolesPyridones

Substanzen

Heparin, Low-Molecular-WeightAnticoagulantsapixabanPyrazolesPyridones

Autor:innen und Institutionen

  • General Surgery Residency, Spectrum Health, Grand Rapids, MI, USA.
  • Michigan State College of Human Medicine, Grand Rapids, MI, USA.
  • Spectrum Health, Grand Rapids, MI, USA.

ORCID-Profile: Mathew Chung

Zitieren

APA

Kelly, K., Blanck, L. M., Lim, K., Norman, A., Roberto, C. V., Assifi, M. M., Wright, G. P., & Chung, M. (2023). Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis. The American Surgeon™. https://doi.org/10.1177/00031348231156778

Vancouver

Kelly K, Blanck LM, Lim K, Norman A, Roberto CV, Assifi MM, et al. Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis. The American Surgeon™. 2023. doi:10.1177/00031348231156778

BibTeX
@article{Kelly2023,
  author = {Kelly, Kathrine and Blanck, Lauren M and Lim, Kelvin and Norman, Alexa and Roberto, Charlaine V and Assifi, M Mura and Wright, G Paul and Chung, Mathew},
  title = {Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis},
  journal = {The American Surgeon™},
  year = {2023},
  doi = {10.1177/00031348231156778}
}
Kostenlos starten →